Fosun Pharmaceutical received NMPA approval to initiate a clinical trial of FXB-0871 (TEV-56278) for locally advanced or metastatic solid tumors. The regulatory green light authorizes the start of the study, marking progress in Fosun’s oncology pipeline. While trial design and endpoints were not detailed in the excerpt, the approval indicates that the company has satisfied China’s requirements for initiating human testing. For biotech watchers, the development adds to the growing count of Chinese oncology programs reaching active clinical phases, supported by ongoing investment in translational oncology. The next key milestones will be the reported safety profile and early efficacy signals that determine whether FXB-0871 secures further registrational pathways.